Loading...
BIOL.Q logo

BIOLASE, Inc.OTCPK:BIOL.Q Aktienübersicht

Marktkapitalisierung US$274.5k
Aktienkurs
US$0.000001
Mein Marktwert
n/v
1Y-92.9%
7D9.6%
1D
Wert des Portfolios
​
Siehe

BIOLASE, Inc.

OTCPK:BIOL.Q Lagerbericht

Marktkapitalisierung: US$274.5k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BIOLASE (BIOL.Q) Aktienübersicht

BIOLASE, Inc. und ihre Tochtergesellschaften entwickeln, produzieren, vermarkten und verkaufen Lasersysteme für Zahnärzte und deren Patienten in den Vereinigten Staaten und international. Mehr Details

BIOL.Q grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung2/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit0/6
Dividenden0/6

Risikoanalyse

Hat keine nennenswerte Marktkapitalisierung ($274K)

Negatives Eigenkapital

Sehr volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Die Erträge sind in den letzten 5 Jahren um 7.3% pro Jahr zurückgegangen

+ 2 mehr Risiken

BIOL.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

BIOLASE, Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für BIOLASE
Historische Aktienkurse
Aktueller AktienkursUS$0.0097
52-Wochen-HochUS$0.26
52-Wochen-TiefUS$0.004
Beta0.82
1 Monat Veränderung4.28%
3 Monate Veränderung21.88%
1 Jahr Veränderung-92.93%
3 Jahre Veränderung-100.00%
5 Jahre Veränderung-100.00%
Veränderung seit IPO-100.00%

Aktuelle Nachrichten und Updates

Recent updates

Seeking Alpha • Aug 31

Biolase partners with dental speciality programs across U.S.

Biolase (NASDAQ:BIOL) announced strategic plan to partner with postgraduate dental specialty programs throughout North America for dentists to adopt its Waterlase technology. "We believe investing in postgraduate programs will accelerate the adoption curve and be mutually beneficial. The residents will learn the benefits of all tissue laser technology in dentistry while providing the latest in patient care," the company said. The Waterlase dental laser offers faster procedures to less invasive treatment option.
Seeking Alpha • Jul 21

BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity

BIOLASE is a name we advocate investors to steer clear of in long-only, equity focused portfolios. The company displays numerous characteristics investors are agnostic to in FY22, particularly around profitability and equity beta. BIOL's earnings model sees it print ongoing operating losses and weak FCF conversion, requiring sustained capital injections for liquidity. We've priced the stock at $4 suggesting the market has it fairly valued. We are neutral on BIOLASE, Inc. (BIOL) shares and note the company is ill-positioned to deliver capital appreciation in the coming periods. BIOL's earnings model involves razor thin gross margins that feed minimal amounts of operating income to free cash below the bottom line. Hence, it prints a series of operating losses that require continuous external capital injection in order to maintain liquidity. A review of the company's products is best left for a separate review; hence, we will take a hard data approach to gauge the investment debate. We price BIOL at $4 per share, and note it displays numerous characteristics investors are shying away from in their positioning for FY23. We rate BIOL neutral. Exhibit 1. BIOL 6-month price action Data: Updata Market factors show divergence from equity premia Investors have finally wound back the high-beta trade of FY20/21' and are paying attention to quality and value factors once more. Fundamental momentum and earnings quality are more imperative than ever. Companies with proven market fit, strong economics, and above all, defensible business models have strengthened against benchmarks whilst reducing correlations in doing so. Later we demonstrate the weakness in BIOL's earnings model. However, it's abundantly clear BIOL displays a lack of the alternative premia investors are paying a premium for in FY22. Firstly, the stock has declined in relative strength against the benchmark sharply since April, as seen below. Meanwhile, after a small blip, its equity beta has remained substantially high at 1.2 indicating it is a high-beta play that will likely to have been punished this YTD. This much is true – BIOL has caught sellers all the way from $11, posting a 59% loss since January. Exhibit 2. BIOL has weakened against the benchmark as equity beta remains high – factors investors are agnostic to in FY22 Data: Updata Unsurprisingly, the stock has also weakened against the US medical devices and health care equipment sector since equity markets began to downturn in October 2021. As seen in Exhibit 3, BIOL now trades at a 12-month low relative to the sector. As investors step up in quality and resiliency, they will look to defensible characteristics and high return on capital amid the shifting rates regime. On this, BIOL lags and hence potentially explains the relative weakness to the traditionally defensive US medtech sector. Exhibit 3. BIOL continues to weaken against US medtech & health care equipment, as investors step up in quality in the space Data: Updata Fundamental Factors Don't Stack Up Q1 FY22 sales came in at ~$10 million, ~25% YoY growth. Performance was underlined by a 43% YoY gain to US laser systems and a 35% YoY gain to BIOLASE specific procedures. International turnover also grew 15% and have been steady for the last few quarters. On a marginal basis, the company lifted gross margin 13 percentage points to 47% – above pre-pandemic gross margin of 34%. This is still razor thin however, and leaves little headroom down the P&L for margin elasticity. On this, management notes it successfully passed costs through in Q1, printing operating expenses of ~$9 million, in line from last year. To achieve is guided 10% YoY revenue growth in FY22/23', BIOL has what it calls a 3-pronged strategy that's been in situ since 2021. Chief to the first 'prong' is specialist adoption of the laser technology. To this effect, BIOL formed an academy to market the dental lasers amongst orthodontists, endodontists and periodontists back in 2021. It did this to hopefully drive up the acceleration of new accounts, management said on the Q1 earnings call. Its second 'prong' is more of a speculative growth play at the US general practitioner dentist ("GPD") market, by our estimate. It notes there are ~150,000 of these generalists in the US, and makes some very generous assumptions around its ability to penetrate this segment. Per CEO John Beaver on the Q1 earnings call, "[i]f an additional 5% of GPDs adopted our laser in the US, it would generate $225 million in laser revenue, not including consumables," on the Q1 earnings call. Again, these are very generous assumptions around its addressable market that haven't yet begun to materialise. To get to $225 million from an additional 5% of GPD adoption, BIOL says it expanded its Waterlase Exclusive Trial program. This lets GPDs utilise the system in their office for ~45 days. Included is 2 days of in-person training and mentor support, all at no extra cost. Afterwards, the clinician is prompted to buy the laser. Firstly this is a timely and costly way of trying to convert GPDs. It takes longer than 1 30 day payment cycle and there's no incentive structure to use the device on trial. Moreover, conversion has been light on these events to date. It held 30 in FY21 and 12 so far this YTD. Each had 4–8 GPDs participate, management said, 9.5%–19% participation rate. The third 'prong' is driving the adoption of its lasers to corporate dentists. It has ongoing trials with 80% of the largest DSOs in the US, which targets new graduates as many new dentists are employed by the DSOs straight from dental school. BIOL hopes to educate them on using the lasers, and try and make lasers an "essential part of their practice moving forward". Hence, when out in practice, they might be drawn to BIOL lasers. Again, fraught with assumption, by estimate, and it relies on the premise these dentists will prefer BIOL lasers in the first place. There's no evidence to suggest this will be the case. In that vein, BIOL's profitability characteristics are an equity risk looking ahead. Investors have turned away from rewarding top-line growth in FY22 and are rewarding bottom-line fundamentals and profitability instead. Whilst it continues to build its top line at ~25% YoY, this doesn't pull through the P&L to earnings and FCF. As such, BIOL has printed a series of operating losses since FY15 to date, whilst realizing a negative FCF yield across this entire time span. Moreover, sales were extremely lumpy pre-Covid, and haven't grown back past these levels. Exhibit 4. Series of lumpy sales performance and operating losses sees weak FCF conversion
Seeking Alpha • Jul 01

BIOLASE amends senior secured term loan with SWK Funding

BIOLASE (NASDAQ:BIOL) has amended its senior secured term loan with SWK Funding LLC by extending the interest-only period of the loan by two quarters to November 2023 and reduces the minimum Consolidated Unencumbered Liquid Assets from $7,500,000 to $5,500,00. The company used a portion of the proceeds from its recent equity offering to prepay $1M of the outstanding loan balance. John Beaver, President and Chief Executive Officer of BIOLASE said, "This prepayment and amendment will result in lower interest expense while also increasing the Company's liquidity."
Seeking Alpha • Mar 21

BIOLASE: Bad News Across The Board - Sell

Company reports Q4 results in-line with preliminary numbers and provides a rather disappointing outlook. Profitability target delayed by another year. Muted growth in combination with the decision to keep pricing steady likely to result in another year of material cash usage. On the conference call, management affirmed its intent to conduct a reverse stock split before the May 23 deadline. With profitability delayed by another year and the likely requirement to raise additional capital in 2023, investors should consider selling existing positions ahead of the upcoming reverse stock split.
Analyseartikel • Feb 24

Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Jan 11

BIOLASE - Speculative Buy After Strong Preliminary Q4 Results

Company releases very strong preliminary Q4 top-line numbers with revenues now eclipsing pre-COVID numbers. Despite solid execution, shares have retreated by 80% from recent highs as investors remain wary of ongoing cash usage and a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Shares are trading at bargain levels at just 0.7x EV/Revenue. Despite poor market sentiment, highly speculative investors should consider a rebound trade in the shares given management's solid execution, bargain valuation and expectations for EBITDA profitability at the end of the year.
Seeking Alpha • Nov 24

BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors

Company continues to outperform expectations as sales and margins recover from last year's COVID-related setback. Despite solid execution, shares have retreated by more than 70% from recent highs as investors remain wary of a potential reverse stock split to regain Nasdaq listing compliance. Biolase continues to burn sizeable amounts of cash with adjusted EBITDA profitability not expected before Q4/FY2022. Stock looks cheap from a fundamental perspective, trading at just 1.25x EV/Revenue. On Tuesday, Biolase announced another 180-day Nasdaq extension and improved credit terms with its primary lender thus providing a major catalyst for the beaten down shares but only the most speculative investors/traders you consider scaling into the shares at current levels given ongoing cash burn and the likely requirement to execute a reverse stock split next year.

Aktionärsrenditen

BIOL.QUS Medical EquipmentUS Markt
7D9.6%4.4%1.1%
1Y-92.9%-17.9%28.7%

Rendite im Vergleich zur Industrie: BIOL.Q unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -17.9% erzielte.

Rendite vs. Markt: BIOL.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 28.7 erzielte.

Preisvolatilität

Is BIOL.Q's price volatile compared to industry and market?
BIOL.Q volatility
BIOL.Q Average Weekly Movement33.9%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von BIOL.Q war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: BIOL.QDie wöchentliche Volatilität (34%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
1984157John Beaverwww.biolase.com

BIOLASE, Inc. entwickelt, produziert, vermarktet und verkauft zusammen mit seinen Tochtergesellschaften Lasersysteme für Zahnärzte und deren Patienten in den Vereinigten Staaten und international. Die Dentallasersysteme des Unternehmens ermöglichen Zahnärzten, Parodontologen, Endodontologen, Kinderzahnärzten, Kieferchirurgen und anderen Dentalspezialisten die Durchführung einer Reihe von minimalinvasiven zahnmedizinischen Eingriffen, einschließlich kosmetischer, restaurativer und komplexer chirurgischer Anwendungen. Das Unternehmen bietet Waterlase All-Tissue-Dental-Lasersysteme zum Schneiden von Weich- und Hartgewebe, Dioden-Soft-Tissue-Lasersysteme für Weichgewebe, Hygiene, temporäre Schmerzlinderung, Zahnaufhellung und kosmetische Verfahren sowie den Epic Hygiene-Laser zur Behandlung von nicht-chirurgischer Parodontitis und zur Verbesserung der klinischen Produktion.

BIOLASE, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von BIOLASE im Vergleich zum Marktanteil des Unternehmens?
BIOL.Q grundlegende Statistiken
MarktanteilUS$274.48k
Gewinn(TTM)-US$15.97m
Umsatz(TTM)US$46.03m
0.0x
Kurs-Umsatz-Verhältnis
0.0x
Kurs-Gewinn-Verhältnis

Ist BIOL.Q zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
BIOL.Q Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$46.03m
Kosten der EinnahmenUS$30.18m
BruttogewinnUS$15.85m
Sonstige AusgabenUS$31.82m
Gewinn-US$15.97m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-0.44
Bruttomarge34.44%
Nettogewinnspanne-34.69%
Schulden/Eigenkapital-Verhältnis-486.1%

Wie hat sich BIOL.Q auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2025/03/12 20:45
Aktienkurs zum Tagesende2025/03/12 00:00
Gewinne2024/09/30
Jährliche Einnahmen2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

BIOLASE, Inc. wird von 8 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Edward WooAscendiant Capital Markets LLC
Bruce JacksonBenchmark Company
Kyle BauserColliers Securities